Study on Biomarker-Driven Treatments for Persistent or Returning Rare Ovarian Tumors

Inclusion Criteria

• Have a confirmed diagnosis of a rare type of ovarian, fallopian tube, or primary peritoneal cancer that is not high-grade serous or high-grade endometrioid.
• The cancer must be measurable by scans or tests.
• Have received one to four previous treatments, including at least one platinum-based chemotherapy.
• The cancer must have shown resistance to platinum-based treatments, meaning it progressed during or within six months after the last platinum treatment.
• Provide a tumor sample for genetic testing and estrogen receptor analysis.
• Have a performance status score of 0 or 1, indicating full activity or some restriction in strenuous activities.
• Have adequate blood counts and organ function.
• Women of childbearing potential must agree to use contraception or remain abstinent and not donate eggs during the study.
• Meet any additional specific criteria for the treatment arm they are assigned to.

Exclusion Criteria

• Pregnant or breastfeeding, or planning to become pregnant or breastfeed during the study.
• Have cancer that progressed during or within four weeks after the first platinum treatment.
• Have high-grade serous or high-grade endometrioid ovarian, fallopian tube, or primary peritoneal cancer.
• Have only borderline ovarian tumors or non-epithelial ovarian tumors.
• Have another primary endometrial cancer, unless it meets specific low-risk criteria.
• Have uncontrolled fluid buildup around the lungs, heart, or abdomen that requires frequent drainage.
• Have untreated or worsening cancer that has spread to the brain or central nervous system.
• Have had a severe infection within four weeks before starting the study treatment.
• Have received chemotherapy, radiotherapy, or other specific treatments within 28 days before starting the study treatment.
• Have received hormonal therapy within 14 days before starting the study treatment.
• Must not meet any additional exclusion criteria specific to the treatment arm they are assigned to.